Department of Medicine
-
October 9, 2019
Vaccine study seeks to halt flu’s most severe side effects
Vanderbilt University Medical Center is leading a multicenter national study to evaluate the effectiveness of the influenza vaccine for preventing the flu’s most serious side effects — admission to an intensive care unit (ICU), organ failure and death. -
October 8, 2019
A new regulator of B cell development
New findings establish a role for the pro-inflammatory molecule IL-33 in the early development of antibody-producing B cells. -
October 3, 2019
VICC’s Rathmell honored with Louisa Nelson Award
Kimryn Rathmell, MD, PhD, director of the Division of Hematology and Oncology, received an award that honors women who embody the achievement, vision and inspiration of the founder of a local distillery. -
October 3, 2019
A step toward gastric cancer
New research findings provide insight into the detrimental events that develop in response to H. pylori infection. -
October 3, 2019
Diabetes drug study explores cardiovascular risks for patients with kidney disease
An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease. -
September 25, 2019
Study shines light on architecture of kidney disease
A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues. -
September 25, 2019
Study identifies targeted therapy’s cardiac risks
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.